Two randomized Phase 2 clinical trials of imetelstat in solid tumors continued enrollment throughout 2011: a study in patients with metastatic breast cancer (B014) and a study in patients with advanced non-small cell lung cancer (B012). These two trials require that a sufficient number of progression events occur in order to perform the planned data analyses. Geron anticipates an accrual of events that will allow the company to report top-line data from these two Phase 2 trials by the end of 2012.
◦Two single-arm Phase 2 trials of imetelstat in hematological malignancies were initiated in the first quarter of 2011 to evaluate the impact of the drug on cancer progenitor cells: a study in patients with essential thrombocythemia (B015) and an exploratory study in patients with multiple myeloma (B013). Top-line data from these two trials are expected to be available by the end of 2012.
http://www.reuters.com/article/2012/03/0...
Positive results mean: double/triple
◦Two single-arm Phase 2 trials of imetelstat in hematological malignancies were initiated in the first quarter of 2011 to evaluate the impact of the drug on cancer progenitor cells: a study in patients with essential thrombocythemia (B015) and an exploratory study in patients with multiple myeloma (B013). Top-line data from these two trials are expected to be available by the end of 2012.
http://www.reuters.com/article/2012/03/0...
Positive results mean: double/triple
Geron needs good results to survive. Closed up 1 cent at $1.46 on 753,767 shares. Three month avg. volume is 760,605 shares.
ACTC closed down just a little at 0.072 on 2.6 million shares. Three month avg. volume is 24 million shares.
AAPL still going down closed at $546.08. Will buy more but will wait.
Good luck in this rigged casino,
No comments:
Post a Comment